These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 32597089)
21. The expression of Hexokinase 2 and its hub genes are correlated with the prognosis in glioma. Huang Y; Ouyang F; Yang F; Zhang N; Zhao W; Xu H; Yang X BMC Cancer; 2022 Aug; 22(1):900. PubMed ID: 35982398 [TBL] [Abstract][Full Text] [Related]
22. Correlation of AIF-1 Expression with Immune and Clinical Features in 1270 Glioma Samples. Rao M; Yang Z; Huang K; Liu W; Chai Y J Mol Neurosci; 2022 Feb; 72(2):420-432. PubMed ID: 34939148 [TBL] [Abstract][Full Text] [Related]
23. Selenoprotein GPX1 is a prognostic and chemotherapy-related biomarker for brain lower grade glioma. Chen X; Fu G; Li L; Zhao Q; Ke Z; Zhang R J Trace Elem Med Biol; 2022 Dec; 74():127082. PubMed ID: 36155420 [TBL] [Abstract][Full Text] [Related]
24. Identification and validation of an individualized prognostic signature of lower-grade glioma based on nine immune related long non-coding RNA. Maimaiti A; Jiang L; Wang X; Shi X; Pei Y; Hao Y; Paerhati H; Zibibula Y; Abudujielili A; Kasimu M Clin Neurol Neurosurg; 2021 Feb; 201():106464. PubMed ID: 33454543 [TBL] [Abstract][Full Text] [Related]
25. ECM2, a prognostic biomarker for lower grade glioma, serves as a potential novel target for immunotherapy. Cheng X; Liu Z; Liang W; Zhu Q; Wang C; Wang H; Zhang J; Li P; Gao Y Int J Biochem Cell Biol; 2023 May; 158():106409. PubMed ID: 36997057 [TBL] [Abstract][Full Text] [Related]
26. Expression and prognostic value of long non-coding RNA H19 in glioma via integrated bioinformatics analyses. Xiao Y; Zhu Z; Li J; Yao J; Jiang H; Ran R; Li X; Li Z Aging (Albany NY); 2020 Feb; 12(4):3407-3430. PubMed ID: 32081833 [TBL] [Abstract][Full Text] [Related]
27. Bioinformatics analysis of C3 in brain low-grade gliomas as potential therapeutic target and promoting immune cell infiltration. Wu S; Miao K; Wang L; Ma Y; Wu X Med Oncol; 2022 Jan; 39(2):27. PubMed ID: 35018510 [TBL] [Abstract][Full Text] [Related]
28. CNPY4 is a potential promising prognostic-related biomarker and correlated with immune infiltrates in gliomas. Li JW; Huang QR; Mo LG Medicine (Baltimore); 2022 Aug; 101(33):e30044. PubMed ID: 35984129 [TBL] [Abstract][Full Text] [Related]
29. S100A gene family: immune-related prognostic biomarkers and therapeutic targets for low-grade glioma. Zhang Y; Yang X; Zhu XL; Bai H; Wang ZZ; Zhang JJ; Hao CY; Duan HB Aging (Albany NY); 2021 Jun; 13(11):15459-15478. PubMed ID: 34148033 [TBL] [Abstract][Full Text] [Related]
30. [Single-cell transcriptome analysis of multigrade glioma heterogeneity and immune microenvironment revealed potential prognostic biomarkers]. Liu J; Xu K; Ma L; Wang Y Sheng Wu Gong Cheng Xue Bao; 2022 Oct; 38(10):3790-3808. PubMed ID: 36305410 [TBL] [Abstract][Full Text] [Related]
31. Chen Z; Cui S; Dai Y; Lu C; Zhang H; Zhao W; Yan H; Zhang Y Oxid Med Cell Longev; 2022; 2022():7595230. PubMed ID: 36193074 [TBL] [Abstract][Full Text] [Related]
32. Expression, Prognosis, and Immune Infiltrates Analyses of E2Fs in Human Brain and CNS Cancer. Liao P; Han S; Qu H Biomed Res Int; 2020; 2020():6281635. PubMed ID: 33381564 [TBL] [Abstract][Full Text] [Related]
33. PTPRN Serves as a Prognostic Biomarker and Correlated with Immune Infiltrates in Low Grade Glioma. Li P; Chen F; Yao C; Zhu K; Zhang B; Zheng Z Brain Sci; 2022 Jun; 12(6):. PubMed ID: 35741647 [TBL] [Abstract][Full Text] [Related]
34. Next-generation sequencing identifies HOXA6 as a novel oncogenic gene in low grade glioma. Xiulin J; Wang C; Guo J; Wang C; Pan C; Nie Z Aging (Albany NY); 2022 Mar; 14(6):2819-2854. PubMed ID: 35349479 [TBL] [Abstract][Full Text] [Related]
35. Elevated expression of mitochondrial transcription elongation factor (TEFM) predicts poor prognosis in low grade glioma-an analysis of the Cancer Genome Atlas (TCGA) dataset. Li S; Wang W; Zi J; Sun M; Mei W; Yang N; Zhang R; Yu M; Xiong W Transl Cancer Res; 2020 May; 9(5):3610-3622. PubMed ID: 35117724 [TBL] [Abstract][Full Text] [Related]
36. Co-amplified with PDGFRA, IGFBP7 is a prognostic biomarker correlated with the immune infiltrations of glioma. Wang H; Wang X; Xu L; Zhang J Cancer Med; 2023 Feb; 12(4):4951-4967. PubMed ID: 36043552 [TBL] [Abstract][Full Text] [Related]
37. Mutational profiling of low-grade gliomas identifies prognosis and immunotherapy-related biomarkers and tumour immune microenvironment characteristics. Lin WW; Ou GY; Zhao WJ J Cell Mol Med; 2021 Nov; 25(21):10111-10125. PubMed ID: 34597473 [TBL] [Abstract][Full Text] [Related]
38. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures. Zhang X; Wang Y; A G; Qu C; Chen J Front Immunol; 2021; 12():721030. PubMed ID: 34531868 [TBL] [Abstract][Full Text] [Related]
39. MELK is a prognostic biomarker and correlated with immune infiltration in glioma. Yang H; Zhou H; Wang G; Tian L; Li H; Zhang Y; Xue X Front Neurol; 2022; 13():977180. PubMed ID: 36353126 [TBL] [Abstract][Full Text] [Related]
40. Immune Infiltration-Related Signature Predicts Risk Stratification and Immunotherapy Efficacy in Grade II and III Gliomas. Luo C; Liu Z; Ye W; Liu F Front Cell Dev Biol; 2021; 9():756005. PubMed ID: 34805164 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]